Atogepant (Aquipta®) for prophylaxis of episodic migraine. HTA ID: 23059

Assessment Status Rapid Review Complete
HTA ID 23059
Drug Atogepant
Brand Aquipta®
Indication Atogepant is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month.
Assessment Process
Rapid review commissioned 20/09/2023
Rapid review completed 26/10/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atogepant on the basis of the proposed price relative to currently available therapies.